Articles
FDA issues finalized guidelines for use of in vitro diagnostics in oncology drug trials and warnings on vaping; new findings report patients bear more costs when MBC treatment is not concordant with NCCN guidelines. Read More ›
On September 26, 2019, the FDA approved daratumumab (Darzalex; Janssen) in combination with bortezomib, thalidomide, and dexamethasone for the treatment of newly diagnosed patients with multiple myeloma who are eligible for autologous stem-cell transplant (ASCT). The FDA granted this application priority review. Read More ›
The August issue of The Oncology Pharmacist (TOP) features a presentation from the 2019 Hematology/Oncology Pharmacy Association Annual Conference that explores the timely topic of precision medicine and its potential role in guiding treatment decisions that can improve the lives of patients with cancer. Read More ›
By Phoebe Starr
The FDA has announced the launch of an oncology-specific pilot program for physicians and patients who need access to investigational therapies. Read More ›
By Wayne Kuznar
Expanded data from an early phase 1/2 clinical trial showed that treatment with repotrectinib, an investigational tyrosine kinase inhibitor (TKI) with potent selectivity against tumors with ROS1 rearrangement, induced a response in 9 of 11 patients with TKI-naïve, ROS1-fusion–positive non–small-cell lung cancer (NSCLC). Read More ›
By Phoebe Starr
Results from a new clinical trial suggest that limited access to care is the main contributing factor to the disparities in outcomes that exist between African American patients and white patients with cancer. Read More ›
By Chase Doyle
Formed 10 years ago with the Affordable Care Act, the Centers for Medicare & Medicaid Services (CMS) Center for Medicare & Medicaid Innovation (CMMI) has been tasked with developing new payment and delivery models designed to improve the efficiency of specialty care. Read More ›
By Wayne Kuznar
High-grade gliomas harboring the histone 3 (H3) K27M mutation are lethal brain tumors associated with a poor prognosis. Read More ›
By Wayne Kuznar
Approximately one-fourth of children, adolescents, and young adults with advanced cancer were eligible for a targeted therapy after genotyping their tumors in the screening protocol of the Pediatric Molecular Analysis for Therapy Choice (MATCH) clinical trial. Read More ›
By Phoebe Starr
Reduced-dose chemotherapy is as effective as full-dose chemotherapy in frail elderly patients with advanced gastroesophageal cancer, according to results of the phase 3 GO2 clinical trial presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. Read More ›